- Home
- OLMA vs VERV Comparison
OLMA vs VERV Comparison
Compare OLMA & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLMA
- VERV
- Stock Information
- Founded
- OLMA 2006
- VERV 2018
- Country
- OLMA United States
- VERV United States
- Employees
- OLMA N/A
- VERV N/A
- Industry
- OLMA Biotechnology: Pharmaceutical Preparations
- VERV Medicinal Chemicals and Botanical Products
- Sector
- OLMA Health Care
- VERV Health Care
- Exchange
- OLMA Nasdaq
- VERV Nasdaq
- Market Cap
- OLMA 420.2M
- VERV 475.0M
- IPO Year
- OLMA 2020
- VERV 2021
- Fundamental
- Price
- OLMA $5.66
- VERV $6.14
- Analyst Decision
- OLMA Strong Buy
- VERV Strong Buy
- Analyst Count
- OLMA 5
- VERV 4
- Target Price
- OLMA $26.25
- VERV $25.75
- AVG Volume (30 Days)
- OLMA 1.3M
- VERV 1.5M
- Earning Date
- OLMA 03-10-2025
- VERV 02-25-2025
- Dividend Yield
- OLMA N/A
- VERV N/A
- EPS Growth
- OLMA N/A
- VERV N/A
- EPS
- OLMA N/A
- VERV N/A
- Revenue
- OLMA N/A
- VERV $24,396,000.00
- Revenue This Year
- OLMA N/A
- VERV $97.47
- Revenue Next Year
- OLMA N/A
- VERV N/A
- P/E Ratio
- OLMA N/A
- VERV N/A
- Revenue Growth
- OLMA N/A
- VERV 219.91
- 52 Week Low
- OLMA $4.60
- VERV $4.31
- 52 Week High
- OLMA $16.78
- VERV $19.34
- Technical
- Relative Strength Index (RSI)
- OLMA 41.95
- VERV 53.75
- Support Level
- OLMA $4.60
- VERV $5.32
- Resistance Level
- OLMA $5.83
- VERV $6.87
- Average True Range (ATR)
- OLMA 0.54
- VERV 0.52
- MACD
- OLMA 0.15
- VERV -0.00
- Stochastic Oscillator
- OLMA 59.55
- VERV 56.74
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.